A groundbreaking clinical trial shows that semaglutide, a medication already used for weight loss and diabetes management, can reverse liver scarring and inflammation in patients with advanced metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. The phase 3 ESSENCE trial found that approximately two-thirds of patients receiving semaglutide 2.4 mg weekly achieved resolution of liver inflammation without worsening scarring, compared to about one-third on placebo .

What Is MASH and Why Does It Matter?

MASH is the inflammatory stage of metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where excess fat builds up inside the liver, often without any obvious symptoms. Unlike alcohol-related liver disease, MASLD develops from metabolic factors like obesity, high blood sugar, and high blood pressure. Roughly one in four people with fatty liver disease progress to MASH, where inflammation and cell damage begin to scar the liver tissue .

The critical window for intervention is when patients have F2-F3 fibrosis, meaning moderate to advanced scarring. At this stage, the risk of cirrhosis, liver cancer, and liver-related death rises sharply, but treatment can still prevent further progression. The ESSENCE trial specifically targeted this high-risk group, enrolling 800 participants with biopsy-confirmed MASH and significant fibrosis .

How Did Semaglutide Perform in the Trial?

The results were striking when compared to existing treatment options. In the intention-to-treat biopsy population, approximately two-thirds of semaglutide-treated patients achieved resolution of steatohepatitis without worsening fibrosis, compared with about one-third in the placebo group. This represented an absolute difference of 25 to 30 percentage points, with a number needed to treat of roughly 3 to 4, meaning only three to four patients needed treatment for one to benefit .

For fibrosis improvement specifically, approximately one-third of semaglutide patients achieved at least one stage of fibrosis improvement without worsening inflammation, compared with approximately one-fifth on placebo. This translated to an absolute benefit of 12 to 15 percentage points, with a number needed to treat of 6 to 8 .

Beyond liver-specific outcomes, semaglutide produced substantial weight loss of approximately 10 to 11 percent, compared to about 2 percent with placebo. This weight reduction coincided with broad improvements in cardiometabolic health, including better blood sugar control, lower blood pressure, improved cholesterol levels, and reduced inflammatory markers .

What Do Non-Invasive Liver Tests Show?

The trial also measured improvements using non-invasive assessments that don't require liver biopsy. These included the enhanced liver fibrosis score, vibration-controlled transient elastography (a type of ultrasound that measures liver stiffness), and blood markers of liver damage like aminotransferases (ALT and AST enzymes). All of these measures showed favorable shifts in the semaglutide group, suggesting that the improvements detected on biopsy were reflected in real-world clinical markers .

How to Monitor Your Liver Health if You're at Risk

• Know Your Risk Factors: If you have obesity, type 2 diabetes, high blood pressure, or metabolic syndrome, you are at higher risk for MASLD and should discuss screening with your doctor.
• Get Routine Liver Function Tests: Most MASLD cases are discovered during routine blood work or liver function tests performed for unrelated reasons, so regular checkups are essential for early detection.
• Understand the Progression Stages: Fatty liver without inflammation can be fully reversed with lifestyle changes, but once inflammation develops (MASH), the condition requires closer monitoring and potentially medical intervention to prevent scarring.
• Request Fibrosis Assessment if Diagnosed: If you're diagnosed with MASLD, ask your doctor about non-invasive fibrosis testing, such as transient elastography or blood-based fibrosis markers, to determine your stage and risk level.

Why Is This Finding Important for the Future of Liver Disease Treatment?

Until recently, there were no effective disease-modifying medications for MASH with significant fibrosis. The ESSENCE trial represents a pivotal moment in hepatology, demonstrating that a medication already approved for weight loss and diabetes can be repurposed as a liver-protective therapy. The mechanism appears to involve both weight loss and direct metabolic effects on the liver, though researchers emphasize that the full picture remains to be understood .

The global burden of MASLD is staggering and growing. An estimated 1.3 billion people currently have the condition, representing roughly 16 percent of the global population. Projections suggest this figure will rise 42 percent to 1.8 billion by 2050, driven by rising obesity and high blood pressure rates worldwide . Despite this enormous disease burden, MASLD remains underrecognized and undertreated, with research from the British Liver Trust finding that approximately one-third of MASLD cases are diagnosed at a late stage, when treatment options are more limited .

"The condition has and will continue to have substantial health and economic impacts worldwide. The majority of patients with MASLD are asymptomatic, which is a barrier to MASLD surveillance among at-risk individuals," noted researchers from the Global Burden of Disease study published in The Lancet Gastroenterology and Hepatology.

Global Burden of Disease Study Researchers, The Lancet Gastroenterology and Hepatology

The challenge is that MASLD often produces no obvious symptoms, or symptoms that are mistaken for less serious problems. This means many people with the condition don't know they have it until significant damage has already occurred. Earlier detection and improved management, as demonstrated in the ESSENCE trial, may slow progression to more severe disease and prevent the need for liver transplantation .

What Questions Remain About This Treatment?

While the 72-week results are impressive, researchers emphasize that histologic changes must ultimately be linked to long-term clinical outcomes. The ongoing 240-week follow-up in ESSENCE will be critical for determining whether semaglutide-driven improvements in liver scarring and inflammation translate into reductions in cirrhosis, liver cancer, and liver-related death .

Additionally, the ESSENCE population was highly representative of the obese and diabetic MASH phenotype, but had limited representation of "lean" MASH and certain ethnic groups, such as Black patients. This constrains generalizability to those subpopulations, an issue shared by many MASH trials. Researchers also note that combinatorial approaches targeting complementary metabolic and hepatic pathways may define the next phase of MASLD management, suggesting that semaglutide may eventually be combined with other emerging therapies for even greater benefit .